SGP Stock Price, Performance & Company Data

13:30

15:10

16:45

18:25

20:00

About SpyGlass Pharma, Inc.

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Ticker

$SGP

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Aliso Viejo, United States

Website

www.spyglasspharma.com

SGP Metrics

BasicAdvanced

$753m

-$6.75

Bulls say / Bears say

SpyGlass Pharma raised approximately $150 million in its IPO by selling 9.4 million shares at $16 per share, demonstrating robust investor demand for its late-stage pipeline (Reuters).

Shares of SGP jumped as much as 50% in their Nasdaq Global Select Market debut, reflecting strong market enthusiasm for the company’s sustained-release ophthalmic therapies (Reuters).

As of March 31, 2026, the company held $251.0 million in cash and short-term investments—enough to fund operations through 2028—providing a solid financial runway for its pivotal trials (Investing.com).

Enrollment in the registrational Phase 3 trials of the BIM-IOL System is not expected to complete until 2027, pushing a potential NDA submission and commercial launch into 2028 at the earliest (MarketScreener).

SpyGlass Pharma’s net loss for the year ended December 31, 2025 widened 37% to $39.9 million, with general and administrative expenses jumping 73% year-over-year, raising concerns about its high cash burn (Reuters).

SpyGlass faces a trade-secrets lawsuit from Glaukos alleging misuse of over 11,000 confidential documents, posing potential legal liabilities and management distraction (Bloomberg Law).

Data summarised monthly by Lightyear AI. Last updated on 31 Jul 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

SpyGlass Pharma raised approximately $150 million in its IPO by selling 9.4 million shares at $16 per share, demonstrating robust investor demand for its late-stage pipeline (Reuters).

Shares of SGP jumped as much as 50% in their Nasdaq Global Select Market debut, reflecting strong market enthusiasm for the company’s sustained-release ophthalmic therapies (Reuters).

SpyGlass faces a trade-secrets lawsuit from Glaukos alleging misuse of over 11,000 confidential documents, posing potential legal liabilities and management distraction (Bloomberg Law).

Data summarised monthly by Lightyear AI. Last updated on 31 Jul 2026.

About SpyGlass Pharma, Inc.

Ticker

Employees

SGP Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy $SGP

Lightyear

Legal

Work with us

Bulls say / Bears say

SpyGlass Pharma, Inc./$SGP

About SpyGlass Pharma, Inc.

Ticker

Employees

SGP Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Bulls say / Bears say